OBJECTIVE: This study was undertaken to determine whether progestational agents, initiated in the second trimester of pregnancy, reduce the risk of delivery less than 37 weeks, among women at increased risk of spontaneous preterm birth. STUDY DESIGN: Medline, pre-Medline, EMBASE, and Cochrane Central Register of Controlled Trials were searched. Randomized controlled trials with less than 20% lost to follow-up were included. RESULTS: Three trials were eligible for inclusion. There was a significant reduction in risk of delivery less than 37 weeks with progestational agents (relative risk [95% CI] = 0.57 [0.36-0.90]). There was no significant effect on perinatal mortality or serious neonatal morbidity. CONCLUSION: Progestational agents, initiated in the second trimester of pregnancy, may reduce the risk of delivery less than 37 weeks' gestation, among women at increased risk of spontaneous preterm birth, but the effect on neonatal outcome is uncertain. Larger randomized controlled trials are required to determine whether this treatment reduces perinatal mortality or serious neonatal morbidity.
OBJECTIVE: This study was undertaken to determine whether progestational agents, initiated in the second trimester of pregnancy, reduce the risk of delivery less than 37 weeks, among women at increased risk of spontaneous preterm birth. STUDY DESIGN: Medline, pre-Medline, EMBASE, and Cochrane Central Register of Controlled Trials were searched. Randomized controlled trials with less than 20% lost to follow-up were included. RESULTS: Three trials were eligible for inclusion. There was a significant reduction in risk of delivery less than 37 weeks with progestational agents (relative risk [95% CI] = 0.57 [0.36-0.90]). There was no significant effect on perinatal mortality or serious neonatal morbidity. CONCLUSION: Progestational agents, initiated in the second trimester of pregnancy, may reduce the risk of delivery less than 37 weeks' gestation, among women at increased risk of spontaneous preterm birth, but the effect on neonatal outcome is uncertain. Larger randomized controlled trials are required to determine whether this treatment reduces perinatal mortality or serious neonatal morbidity.
Authors: Ning Xie; Liangliang Liu; Yunqing Li; Celeste Yu; Stephanie Lam; Oksana Shynlova; Martin Gleave; John R G Challis; Stephen Lye; Xuesen Dong Journal: Mol Endocrinol Date: 2012-06-05
Authors: Vincenzo Berghella; Dana Figueroa; Jeff M Szychowski; John Owen; Gary D V Hankins; Jay D Iams; Jeanne S Sheffield; Annette Perez-Delboy; Deborah A Wing; Edwin R Guzman Journal: Am J Obstet Gynecol Date: 2010-04 Impact factor: 8.661
Authors: Jeff M Szychowski; Vincenzo Berghella; John Owen; Gary Hankins; Jay D Iams; Jeanne S Sheffield; Annette Perez-Delboy; Deborah A Wing; Edwin R Guzman Journal: J Matern Fetal Neonatal Med Date: 2012-08-24